Suppr超能文献

中心性浆液性脉络膜视网膜病变自发缓解和低强度光动力疗法后 脉络膜厚度的变化。

Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.

机构信息

Department of Ophthalmology, Ewha Womans University, Seoul, Republic of Korea.

出版信息

Eye (Lond). 2013 Mar;27(3):387-91. doi: 10.1038/eye.2012.273. Epub 2013 Jan 4.

Abstract

PURPOSE

To assess the change in subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC) following spontaneous resolution and low-fluence photodynamic therapy (PDT) using the enhanced depth imaging optical coherence tomography (EDI-OCT).

METHODS

A total of 36 consecutive eyes of 36 patients were included in this retrospective study: 16 eyes with spontaneously resolved CSC and 20 eyes with PDT-treated CSC. Best-corrected visual acuity and SFCT were evaluated at each visit until complete absorption of the subretinal fluid. SFCT of 32 normal subjects were also measured, as the control group. Wilcoxon's singed-rank test was used to evaluate the effects of spontaneous resolution and PDT. To compare the SFCT of the eyes with resolved CSC with that of the normal eyes, Mann-Whitney U-test with Bonferroni correction was also employed.

RESULTS

SFCT of patients was 459.16±77.50 μm at the baseline, and decreased to 419.31±54.49μm after a spontaneous resolution (P=0.015). However, SFCT was not normalized in comparison with that of the normal subjects (P<0.001). SFCT in PDT group was also reduced from 416.43±74.01 to 349.50±88.99 μm (P<0.001), with no significant difference with the normal value (P=0.087).

CONCLUSIONS

SFCT in patients with CSC decreased both after spontaneous resolution and low-fluence PDT. However, only in the PDT group, after disappearance of subretinal fluid, did it decrease to that of normal subjects.

摘要

目的

使用增强深度成像光学相干断层扫描(EDI-OCT)评估中心性浆液性脉络膜视网膜病变(CSC)自发消退和低强度光动力疗法(PDT)后中心凹下脉络膜厚度(SFCT)的变化。

方法

本回顾性研究共纳入 36 例 36 只眼:16 只眼为自发性 CSC 消退,20 只眼为 PDT 治疗的 CSC。每次就诊时均评估最佳矫正视力和 SFCT,直到视网膜下液完全吸收。还测量了 32 名正常受试者的 SFCT,作为对照组。Wilcoxon 符号秩检验用于评估自发消退和 PDT 的影响。为了比较消退的 CSC 眼与正常眼的 SFCT,还采用了校正后的 Mann-Whitney U 检验。

结果

患者基线时的 SFCT 为 459.16±77.50 μm,自发消退后降至 419.31±54.49 μm(P=0.015)。然而,与正常对照组相比,SFCT 并未恢复正常(P<0.001)。PDT 组的 SFCT 也从 416.43±74.01 降至 349.50±88.99 μm(P<0.001),与正常值无显著差异(P=0.087)。

结论

CSC 患者在自发消退和低强度 PDT 后 SFCT 均降低。然而,只有在 PDT 组,当视网膜下液消失后,SFCT 才降低至正常水平。

相似文献

2
Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Acta Ophthalmol. 2012 Dec;90(8):738-43. doi: 10.1111/j.1755-3768.2011.02157.x. Epub 2011 May 17.
3
Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Ophthalmology. 2010 Sep;117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15.
5
Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2155-2161. doi: 10.1007/s00417-019-04426-8. Epub 2019 Jul 31.
6
Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Retina. 2013 Feb;33(2):316-23. doi: 10.1097/IAE.0b013e318280769c.
10
Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Ophthalmologica. 2019;241(2):105-115. doi: 10.1159/000490773. Epub 2018 Aug 15.

引用本文的文献

1
Volumetrically tracking retinal and choroidal structural changes in central serous chorioretinopathy.
Biomed Opt Express. 2023 Sep 29;14(10):5528-5538. doi: 10.1364/BOE.506422. eCollection 2023 Oct 1.
2
Short-Term Outcomes of Cataract Surgery in Patients with a History of Central Serous Chorioretinopathy.
J Ophthalmol. 2021 Jun 24;2021:9952050. doi: 10.1155/2021/9952050. eCollection 2021.
3
Correlation between choroidal structure and smoking in eyes with central serous chorioretinopathy.
PLoS One. 2021 Mar 23;16(3):e0249073. doi: 10.1371/journal.pone.0249073. eCollection 2021.
5
Biomarkers for central serous chorioretinopathy.
Ther Adv Ophthalmol. 2020 Aug 24;12:2515841420950846. doi: 10.1177/2515841420950846. eCollection 2020 Jan-Dec.
7
Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy.
Clin Ophthalmol. 2020 Apr 29;14:1165-1175. doi: 10.2147/OPTH.S242926. eCollection 2020.
9
Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy.
Clin Ophthalmol. 2017 Aug 16;11:1505-1512. doi: 10.2147/OPTH.S139288. eCollection 2017.
10
Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A Meta-Analysis.
PLoS One. 2017 Jan 11;12(1):e0169152. doi: 10.1371/journal.pone.0169152. eCollection 2017.

本文引用的文献

1
Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Retina. 2012 Nov-Dec;32(10):2014-9. doi: 10.1097/IAE.0b013e318242b9ab.
2
Topographical Choroidal Thickness Change Following PDT for CSC: An OCT Case Report.
J Ophthalmol. 2012;2012:347206. doi: 10.1155/2012/347206. Epub 2012 Jan 12.
4
Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy.
Eye (Lond). 2011 Dec;25(12):1635-40. doi: 10.1038/eye.2011.258. Epub 2011 Oct 21.
5
Reproducibility of choroidal thickness measurements across three spectral domain optical coherence tomography systems.
Ophthalmology. 2012 Jan;119(1):119-23. doi: 10.1016/j.ophtha.2011.07.002. Epub 2011 Sep 23.
7
Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy.
Retina. 2011 Sep;31(8):1603-8. doi: 10.1097/IAE.0b013e31820f4b39.
8
Review and update of central serous chorioretinopathy.
Curr Opin Ophthalmol. 2011 May;22(3):166-73. doi: 10.1097/ICU.0b013e3283459826.
10
Central serous chorioretinopathy: an update on pathogenesis and treatment.
Eye (Lond). 2010 Dec;24(12):1743-56. doi: 10.1038/eye.2010.130. Epub 2010 Oct 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验